Oncology

NCCN Study Lends Support for Safety and Efficacy Investigation

May 21st 2020

By Tony Hagen

A study of filgrastim and pegfilgrastim biosimilars demonstrated data are sufficiently large to support an investigation on the effectiveness of these agents.

Biocon Gains EU Manufacturing Certification for India Plants

May 19th 2020

By Tony Hagen

Biocon said a subsidiary’s manufacturing centers in Bengaluru, India, were cleared by European Union authorities for biosimilar production.

Part 1: Ali McBride Discusses ACCC Initiatives and Biosimilar Uptake

May 18th 2020

Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses the anticipated growth for the US biosimilar market and what the ACCC is doing to further uptake efforts.

Samsung Bioepis Reports Clinical Trial Data for Ontruzant

May 14th 2020

By Tony Hagen

In a trio of studies, investigators were able to demonstrate equivalency of Samsung Bioepis’ trastuzumab biosimilar in various settings.

Investigators Propose Different Measures for Biosimilar Equivalence

May 12th 2020

By Deana Ferreri, PhD

Investigators use the HERITAGE trial findings to argue for a more precise way of measuring clinical equivalence for biosimilars.

AryoGen Notches an Advance With Its Bevacizumab Candidate

May 10th 2020

By Tony Hagen

With successful findings from a phase 3 trial of its bevacizumab biosimilar candidate, Iranian company AryoGen Pharmed is a step closer to commercialization of this product.

Teva Moves Further out of Debt and Gains Biosimilar Revenue

May 7th 2020

By The Center for Biosimilars

With 1 biosimilar launch and expanded indications for another biosimilar so far this year, Teva Pharmaceutical Industries reported higher biosimilar revenues in the first quarter of 2020.

Teva, Celltrion Maintain Slender Discount to Rituxan

May 4th 2020

By Tony Hagen

Although Pfizer has offered a more attractive discount for its rituximab biosimilar, Teva Pharmaceutical Industries and Celltrion Healthcare have decided not to match that discount for their own rituximab biosimilar, which is more costly.

Amgen Sees Biosimilar "Give and Take"

May 2nd 2020

By The Center for Biosimilars

Amgen saw biosimilar competition eat a larger share of its innovator drug revenue but also earned some biosimilar pocket money of its own.

Biosimilar Business Roundup: April 2020

May 1st 2020

By The Center for Biosimilars

A smattering of biosimilar launches around the globe and positive results for biosimilar earnings across companies suggested a positive trend in April, despite the ongoing pandemic.